Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016
Summary
Global Markets Directs, Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Review, H1 2016, provides in depth analysis on Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted pipeline therapeutics.
The report provides comprehensive information on the Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1)
- The report reviews Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) Overview 6
Therapeutics Development 7
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Stage of Development 7
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Therapy Area 8
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Indication 9
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Products under Development by Companies 12
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Companies Involved in Therapeutics Development 19
Daiichi Sankyo Company, Limited 19
Galmed Pharmaceuticals Ltd. 20
GlaxoSmithKline Plc 21
Johnson & Johnson 22
Novartis AG 23
Sanofi 24
Xenon Pharmaceuticals Inc. 25
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Drug Profiles 26
Aramchol - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
GSK-1940029 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
SAR-224 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Small Molecule to Inhibit SCD1 for Metabolic Disorders - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
XEN-801 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Dormant Projects 37
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Discontinued Products 38
Stearoyl-CoA Desaturase 1 (SCD-1 or EC1.14.19.1) - Featured News & Press Releases 39
Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease 39
Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study 39
Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne 40
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease 40
Sep 24, 2015: Xenon Pharmaceuticals Announces Initiation of XEN801 Phase 1 Clinical Trial 41
Aug 13, 2015: Galmed Pharmaceuticals Announces the Commencement of Patient Screening in the ARREST Study in the United States and Latin America 42
Mar 09, 2015: Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States 43
Jan 28, 2015: Galmed and Perrigo Execute Manufacturing Agreement for Large-Scale Aramchol API Production 43
Dec 01, 2014: Galmed Pharmaceuticals Completes Analysis of a Pharmacokinetic Study of Aramchol in Healthy Volunteers 44
Nov 13, 2014: Galmed Pharmaceuticals Announces First Administration of Aramchol in its Phase IIa Trial for the Treatment of Cholesterol Gallstones 44
Sep 23, 2014: Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 45
Sep 02, 2014: Galmed Pharmaceuticals Completes Two Chronic Toxicology Studies and Reports No Significant Adverse Events 45
Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 46
Jul 08, 2014: Galmed Announces Publication of Aramchol Phase IIa Trial in the Clinical Gastroenterology and Hepatology Journal 47
Jun 09, 2014: Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50
List Of Tables
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Action, H1 2016 15
Number of Products by Stage and Route of Administration, H1 2016 17
Number of Products by Stage and Molecule Type, H1 2016 18
Pipeline by Daiichi Sankyo Company, Limited, H1 2016 19
Pipeline by Galmed Pharmaceuticals Ltd., H1 2016 20
Pipeline by GlaxoSmithKline Plc, H1 2016 21
Pipeline by Johnson & Johnson, H1 2016 22
Pipeline by Novartis AG, H1 2016 23
Pipeline by Sanofi, H1 2016 24
Pipeline by Xenon Pharmaceuticals Inc., H1 2016 25
Dormant Projects, H1 2016 37
Discontinued Products, H1 2016 38
List Of Figures
Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Top 10 Indication, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy/Combination Products, H1 2016 14
Number of Products by Stage and Mechanism of Actions, H1 2016 15
Number of Products by Routes of Administration, H1 2016 16
Number of Products by Stage and Routes of Administration, H1 2016 16
Number of Products by Stage and Molecule Type, H1 2016 18
